EGFR and breast cancer: Although HER2 is not a marker of BCSCs by itself, different strategies directed against HER2-positive BC have been developed, including monoclonal antibodies that bind to the extracellular domain of HER2, EGFR-HER2 small-molecule kinase inhibitors, and antibody-drug conjugates.